Last reviewed · How we verify
Symbicort pMDI
Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Symbicort pMDI |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (PHASE3)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort pMDI CI brief — competitive landscape report
- Symbicort pMDI updates RSS · CI watch RSS
- AstraZeneca portfolio CI